Morgan Stanley Reiterates Equalweight Rating on Solventum (SOLV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BTIG Starts Solventum (SOLV) at Neutral
September 5, 2024 5:40 AM EDTBTIG analyst Ryan Zimmerman initiates coverage on Solventum (NYSE: SOLV) with a Neutral rating.
The analyst comments "Solventum was spun out of 3M (MMM, Not Rated) in April 2024, creating a global healthcare company that operates in a variety of medical technology segments including Medical/Surgical, Dental, Health Information Systems, and Purification & Filtration with global sales of $8.2B and total addressable markets of $93B+. Historically the business segments within MMM underperformed and... More
